Please assess the completion status of the following clinical trial:

Trial Title: Intestinal Permeability in Obesity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria :~- Control subjects T1:~1. Registered for social security~2. Signed consent form~3. male or female subject between 18 and 65 years old~4. Fasting plasma triglycerides \< 1.5 g/l (\< 1.7 mmol/l)~5. Fasting plasma total cholesterol \< 2.5 g/l (\< 6 mmol/l)~6. fasting glycaemia \< 5,5 mmol/l~7. BMI \<25kg/m² \& \>18 kg/m²~8. Mean systolic blood pressure \<140 mmHg and mean diastolic blood pressure \< 90 mmHg.~Control subjects T2~1. Registered for social security~2. Signed consent form~3. male or female subject between 18 and 70 years old~4. IMC\<25kg/m² et \>18 kg/m²~5. candidate to surgery giving access to jejunal samples~Obese subjects OB:~1. Registered for social security~2. Signed consent form~3. male or female subject between 18 and 65 years old~4. Candidate to bariatric surgery (bypass) with massive (IBMI \>= 40 kg/m²) or severe obesity (BMI between 35 \& 40 kg/m²) with at least one obesity-related comorbidity and with a stable weight (+/-5kg) for the last 3 months, after approval by a multidisciplinary team~Exclusion criteria :~- Control subjects T1:~1. Subject with a history of vascular symptomatic disease in the last 6 months before selection.~2. Subject receiving a treatment that can affect measured parameters~3. Pregnancy~4. Subject with acute or chronic disease that can affect measured parameters or to life-threatening. Including but not limited :~   1. Diabetic subjects~  2. Subject with kidney disease: nephrotic syndrome, chronic renal failure~  3. Subject having a gastrointestinal disorder or disease limiting intestinal absorption (celiac disease), bariatric surgery.~  4. Active inflammatory disease or a history of IBD~5. Subject in a situation that, according to the investigator's opinion could interfere with an optimal participation to the study or constitute a particular risk to the subject~6. Subject in an exclusion period after participating in another clinical trial~7. Adult person subject to legal protection or unable to consent.~8. Persons deprived of their liberty by judicial or administrative decision~Control subjects T2~1. Subject with a history of symptomatic vascular disease (myocardial infarction, angina syndrome threat, surgical or endovascular surgery, stroke, lower limb arteritis symptomatic) of less than 6 months~2. Subject with any acute or chronic disease which may influence the results of the study or to life-threatening. Including but not limiting:~   1. diabetic patients~  2. Subject with kidney disease: nephrotic syndrome, chronic renal failure and / or serum creatinine\> 1.7 times the upper limit of the reference value~3. Adult person subject to legal protection or unable to consent.~4. Persons deprived of their liberty by judicial or administrative decision~Obese subjects candidates for surgery:~1. Subject receiving treatment systemically or topically, which may interfere with the evaluation of the parameters studied (NSAIDs, antibiotics in the previous month)~2. Any disease or psychosocial context making prolonged regular monitoring impossible, which also represents a contraindication for bariatric surgery.~3. Adult person subject to legal protection or unable to consent.~4. Persons deprived of their liberty by judicial or administrative decision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- obese group (Type: EXPERIMENTAL): 40 obese subjects undergoing gastric bypass explored at baseline and 30 explored post-surgery at 6 months
- non-obese control group (T1) (Type: ACTIVE_COMPARATOR): 30 non-obese control subjects investigated for bio-clinical measures, IPT, zonulin, and LPS
- non obese control group undergoing a surgery (T2) (Type: NO_INTERVENTION): 40 non-obese candidates to a surgery that gives access to surgical jejunal samples to measure the expression of tight junctions proteins

Based on this trial design, predict the completion outcome and termination type (if applicable).